MENU
NNNN
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

NNNN stock forecast, quote, news & analysis

Anbio Biotechnology is a medical device company focused on in vitro diagnostics... Show more

NNNN
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement

Why Is Anbio Biotechnology (NNNN) Stock Down -21% Today?

Key Takeaways

  • Anbio Biotechnology (NNNN) shares fell approximately 21% in today’s session.
  • The decline follows the company’s recent IPO and elevated trading levels in prior sessions.
  • Low trailing revenue relative to market capitalization contributed to profit-taking pressure.
  • Broader biotech sector volatility and post-listing adjustments amplified the move.
  • Traders are monitoring upcoming conference participation and further volume trends.

Opening Summary

Anbio Biotechnology is a medical device company focused on developing and manufacturing in vitro diagnostics (IVD) products for human and veterinary health. Shares of NNNN dropped sharply today, closing the prior session at $22.99 before trading as low as the $17.50–$18.20 range, representing a decline of roughly 21%. The move reflects ongoing post-IPO price discovery and valuation reassessment amid limited revenue visibility.

Post-IPO Volatility and Valuation Pressure

NNNN listed on the Nasdaq Global Market following its initial public offering, with shares experiencing significant swings since debut. The company’s trailing twelve-month revenue stands at approximately $9–10 million, supporting a market capitalization that has fluctuated between roughly $800 million and over $1 billion. This disconnect between modest top-line results and elevated equity valuation has fueled repeated rounds of selling as investors recalibrate expectations.

Market Context and Trading Activity

Volume on the session appeared elevated compared with recent averages, consistent with heightened interest following the IPO. The decline occurred while broader biotech and medical device peers showed mixed performance, suggesting the move was driven more by company-specific factors than sector-wide sentiment. Technical levels from the prior week were decisively broken lower, with the stock trading well below its recent highs above $30.

Trending AI Robots

Tickeron’s Trending AI Robots page showcases a curated selection of the platform’s strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI-powered bots across thousands of tickers, with strategies varying by timeframe, risk parameters, and traded symbols. Only the top performers based on recent results are highlighted in this section. Investors seeking automated trading ideas can explore the full range of available bots on the platform.

What Comes Next for NNNN

Market participants will watch for additional details from the company’s planned participation in industry forums, including the KeyBanc Capital Markets Healthcare Forum. Any updates on product approvals, revenue traction, or partnership announcements could influence sentiment. Risks include continued volatility typical of newly listed small-cap biotech names and potential dilution or further valuation compression if growth milestones are delayed.

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

A.I.Advisor
a Summary for NNNN with price predictions
Jun 22, 2026

NNNN's RSI Oscillator entering oversold zone

The RSI Oscillator for NNNN moved into overbought territory on June 22, 2026. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NNNN advanced for three days, in of 86 cases, the price rose further within the following month. The odds of a continued upward trend are .

NNNN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NNNN as a result. In of 26 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for NNNN turned negative on June 03, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 7 similar instances when the indicator turned negative. In of the 7 cases the stock turned lower in the days that followed. This puts the odds of success at .

NNNN moved below its 50-day moving average on June 04, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NNNN crossed bearishly below the 50-day moving average on June 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 2 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NNNN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NNNN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NNNN's P/B Ratio (23.866) is very high in comparison to the industry average of (4.511). P/E Ratio (111.599) is within average values for comparable stocks, (182.659). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.431). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (82.645) is also within normal values, averaging (76.815).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NNNN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 7.5B. The market cap for tickers in the group ranges from 126 to 142.71B. ISRG holds the highest valuation in this group at 142.71B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -2%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was -15%. NXGL experienced the highest price growth at 14%, while RGNT experienced the biggest fall at -56%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was -79%. For the same stocks of the Industry, the average monthly volume growth was -32% and the average quarterly volume growth was 125%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 66
Price Growth Rating: 57
SMR Rating: 84
Profit Risk Rating: 97
Seasonality Score: 24 (-100 ... +100)
View a ticker or compare two or three
NNNN
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Industry PharmaceuticalsOther

Profile
Details
Why Is Anbio Biotechnology (NNNN) Stock Down -21% Today?